menu
    • menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Banner Alzheimer's Institute | National Institute on Aging | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"CAD106","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Banner Alzheimer's Institute | National Institute on Aging | Amgen Inc","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Banner Alzheimer's Institute | National Institute on Aging | Amgen Inc"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"CAD106","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Amgen Inc | Banner Alzheimer's Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CNP520","moa":"Beta-secretase-1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Amgen Inc | Banner Alzheimer's Institute","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Amgen Inc | Banner Alzheimer's Institute"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CNP520","moa":"Beta-secretase-1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Newgam","moa":"Immunoglobulin","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Basimglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Basimglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0.11,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Forbion","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Forbion"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Basimglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Basimglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"Basimglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ EQT Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ EQT Life Sciences"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Olesoxime","moa":"Mitochondrial dysfunction||Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"}]

    Find Neurology Drugs in Phase II/III Clinical Development in SWITZERLAND

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson Diseas...

                            Details : Following oral administration, ADX48621 (dipraglurant) was rapidly absorbed and readily crossed the blood-brain barrier. In vivo, dipraglurant administration was found to dose-dependently impact the various NMS disease models.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 04, 2023

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Noema Pharma

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Noema Pharma

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Forbion

                            Deal Size : $112.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Cap...

                            Details : The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in TN and sei...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 07, 2023

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Forbion

                            Deal Size : $112.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Noema Pharma

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Noema Pharma

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Noema Pharma Receives FDA Fast Track Designation for Basimglurant (NOE-101) in Trigeminal Neuralgia

                            Details : Basimglurant (NOE-101) is a highly selective, potent, and cell-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) for the treatment of trigeminal neuralgia (TN).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 18, 2022

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Noema Pharma

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Noema Pharma

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Noema Pharma Announces Completion of Enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) Validation...

                            Details : NOE-101 (basimglurant), a highly selective, potent, and cell-penetrant negative allosteric modulator of mGlu5 receptors for the management of pain associated with TN.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 06, 2022

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Armistice Master Fund

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Addex Completes $4.2 Million Equity Financing

                            Details : Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 26, 2022

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Armistice Master Fund

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Armistice Master Fund

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Addex Raises $4.2 Million in Equity Financing

                            Details : Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 22, 2022

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Armistice Master Fund

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disea...

                            Details : ADX48621 (Dipraglurant (Immediate Release), as a novel orally available mGlu5 NAM, for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 17, 2022

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Noema Pharma

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Noema Pharma

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

                            Details : Basimglurant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Trigeminal Neuralgia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2022

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-bas...

                            Details : Dipraglurant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 11, 2021

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therap...

                            Details : Dipraglurant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 23, 2021

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth